Thursday - October 15, 2026

IgA Nephropathy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences

(Albany, New York) – October 15, 2026: As per DelveInsight’s assessment, globally, IgA Nephropathy pipeline constitutes 25+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading →

Nontuberculous Mycobacterial Infections Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight

The Key Nontuberculous Mycobacterial Infections Companies in the market include – Insmed, Paratek Pharmaceuticals, MicuRx Pharmaceuticals, Vast Therapeutics, BioVersys, AN2 Therapeutics, and others. (Albany, US), October 15, 2026 – DelveInsight’s ‘Nontuberculous Mycobacteria Infections Market Insights, Epidemiology, and Market Forecast – … Continue reading →

Neuroendocrine Prostate Cancer Market Size in the 7MM is projected to grow at a significant CAGR over the forecast period of 2026-2036 | DelveInsight

The Key Neuroendocrine Prostate Cancer Companies in the market include – Phanes Therapeutics, Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb, Merck, Daiichi Sankyo, Moonlight Bio, SystImmune, and others. (Albany, US), October 15, 2026 – DelveInsight’s ‘Neuroendocrine Prostate Cancer (NEPC) Market … Continue reading →

Rheumatoid Arthritis Clinical Trial Drug Development Pipeline Expands with Contributions from 75+ Key Companies | DelveInsight

The Rheumatoid Arthritis clinical trial analysis report delivers important insights into ongoing research on 75+ pipeline Rheumatoid Arthritis drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 15, 2026 – DelveInsight’s “Rheumatoid Arthritis Pipeline Insight 2026” report … Continue reading →

Oral Mucositis Market Set to Grow Through 2036 as OncoZenge Advances BupiZenge Toward Pivotal Phase III Trial

The oral mucositis market is expected to grow due to the increasing incidence of cancer, rising demand for supportive oncology care, growing research and development activity, and incremental healthcare spending worldwide. The anticipated approval of late- and mid-stage emerging therapies … Continue reading →

Hepatic Encephalopathy Market Set to Grow Through 2030 as Golexanolone and AXA1665 Advance Through Clinical Development

(Albany, US), October 15, 2026 – DelveInsight’s “Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of hepatic encephalopathy, historical and forecasted epidemiology, and market trends in the United States, EU5 (Germany, France, Italy, Spain, … Continue reading →

Small lymphocytic lymphoma Clinical Trial Drug Development Pipeline Expands with Contributions from 70+ Key Companies | DelveInsight

The Small lymphocytic lymphoma clinical trial analysis report delivers important insights into ongoing research on 70+ pipeline Small lymphocytic lymphoma drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 15, 2026, DelveInsight’s “Small Lymphocytic Lymphoma Pipeline Insight, … Continue reading →

Small Cell Lung Cancer Clinical Trial Drug Development Pipeline Expands with Contributions from 100+ Key Companies | DelveInsight

The Small Cell Lung Cancer clinical trial analysis report delivers important insights into ongoing research on 100+ pipeline Small Cell Lung Cancer drugs, clinical strategies, upcoming therapeutics, and commercial analysis. (Albany, US) On October 15, 2026, DelveInsight’s “Small Cell Lung … Continue reading →

Checkpoint-Inhibitor Refractory Cancer Market Set to Grow Through 2036 as Lifileucel Uptake Expands and Next-Generation Immunotherapies Advance

(Albany, US), October 15, 2026 – DelveInsight’s “Checkpoint-Inhibitor Refractory Cancer – Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of checkpoint-inhibitor refractory cancer, historical and forecasted epidemiology, and market trends in the United States, EU4 (Germany, … Continue reading →